Tianchen Bio and Aier Health Submit IND for LP-005, the World’s First Dual C3/C5 Inhibitor

On April 10, the CDE website showed that LP-005, co-developed by LongBio and RxViosn, submitted a clinical trial application in China.

LP-005 is a bifunctional fusion protein developed by LongBio, which can simultaneously inhibit complement C5 and C3. LP-005 specifically binds to human C5 complement protein, preventing its cleavage into C5a and C5b, thereby inhibiting the formation of the membrane attack complex, reducing the risk of thrombotic complications, preventing breakthrough hemolytic events, and avoiding extravascular hemolysis through the inhibition of C3.

In April 2021, RxViosn reached a licensing agreement with LongBio for over 1 billion yuan in total transaction value to acquire global rights to LP-005 for ophthalmic disease indications. According to the agreement, RxViosn is responsible for the clinical development and commercialization of LP-005 for age-related macular degeneration (dry and wet forms).

Currently, only one C3 complement inhibitor (pegcetacoplan, Apellis) and two C5 complement inhibitors (ravulizumab and eculizumab, AstraZeneca) have been approved for marketing globally. No drugs targeting both C3 and C5 have entered the clinical stage. Moreover, the approved C3 or C5 targeted drugs are mainly indicated for paroxysmal nocturnal hemoglobinuria (PNH).

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; for republication, please leave a message or send a notification to the WeChat Official Account backend, specifying the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Live Broadcast

CUBE LIVE